Medarex and Xerion to Collaborate on Antibody Products

An agreement under which the two companies plan to develop fully human therapeutic antibody products has been announced by Xerion Pharmaceuticals AG (Munich, Germany) and Medarex, Inc. (Princeton, NJ, USA).

Under the terms of the contract, Xerion plans to contribute disease-associated targets identified through it Xstream technology, while Medarex expects to generate fully human antibody product candidates against these targets using its UltiMAb Human Antibody Development System. Both companies agree to share equally the costs and responsibilities of resulting product development and intend to jointly commercialize any antibody products resulting from this collaboration.

"We believe that the combination of Xerion's Xstream platform and our UltiMAb technology has the potential to result in novel therapeutics, and we look forward to working with Xerion in this endeavor,” said Donald L. Drakeman, president and CEO of Medarex.

Xerion >> www.xerion-pharma.com
Medarex >> www.medarex.co
(Princeton, NJ, USA; www.medarex.com).

Under the terms of the contract, Xerion plans to contribute disease-associated targets identified through it Xstream technology, while Medarex expects to generate fully human antibody product candidates against these targets using its UltiMAb Human Antibody Development System. Both companies agree to share equally the costs and responsibilities of resulting product development and intend to jointly commercialize any antibody products resulting from this collaboration.

"We believe that the combination of Xerion's Xstream platform and our UltiMAb technology has the potential to result in novel therapeutics, and we look forward to working with Xerion in this endeavor,” said Donald L. Drakeman, president and CEO of Medarex.




Related Links:
Xerion
Medarex